Find Orforglipron Calcium Hydrate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

0

FDA Orange Book

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2212020-52-3, Ly3502970, Chembl4446782, Ly-3502970, 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one, 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one
Molecular Formula
C48H48F2N10O5
Molecular Weight
883.0  g/mol
InChI Key
USUWIEBBBWHKNI-KHIFEHGGSA-N
FDA UNII
7ZW40D021M

Orforglipron Calcium Hydrate
1 2D Structure

Orforglipron Calcium Hydrate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one
2.1.2 InChI
InChI=1S/C48H48F2N10O5/c1-25-18-32(19-26(2)40(25)49)60-42(58-16-15-57(46(58)63)37-11-10-36-33(41(37)50)24-51-55(36)7)39-28(4)56(14-12-34(39)53-60)43(61)38-21-31-20-29(30-13-17-64-47(5,6)23-30)8-9-35(31)59(38)48(22-27(48)3)44-52-45(62)65-54-44/h8-11,15-16,18-21,24,27-28,30H,12-14,17,22-23H2,1-7H3,(H,52,54,62)/t27-,28-,30-,48-/m0/s1
2.1.3 InChI Key
USUWIEBBBWHKNI-KHIFEHGGSA-N
2.1.4 Canonical SMILES
CC1CC1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)C5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7C6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C
2.1.5 Isomeric SMILES
C[C@H]1C[C@]1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)[C@H]5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7[C@@H]6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C
2.2 Other Identifiers
2.2.1 UNII
7ZW40D021M
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Ly3502970

2.3.2 Depositor-Supplied Synonyms

1. 2212020-52-3

2. Ly3502970

3. Chembl4446782

4. Ly-3502970

5. 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one

6. 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one

7. V6g

8. Orforglipron [inn]

9. Orforglipron [usan]

10. Ly3502970 (orforglipron)

11. Owl833

12. Schembl21175277

13. Gtpl12175

14. 7zw40d021m

15. Ex-a7751

16. Bdbm50514045

17. Akos040733262

18. Glp-1 Receptor Agonist 1;orforglipron

19. Ms-31635

20. Hy-112185

21. Cs-0043632

22. 1,2,4-oxadiazol-5(2h)-one, 3-[(1s,2s)-1-[2-[[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2,3-dihydro-2-oxo-1h-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5h-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4s)-tetrahydro-2,2-dimethyl-2h-pyran-4-yl]-1h-indol-1-yl]-2-methylcyclopropyl]-

23. 3-[(1s,2s)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4s)-2,2-dimethyloxan-4-yl]-1h-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5h)-ide

2.4 Create Date
2019-01-28
3 Chemical and Physical Properties
Molecular Weight 883.0 g/mol
Molecular Formula C48H48F2N10O5
XLogP36.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count10
Rotatable Bond Count7
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area144
Heavy Atom Count65
Formal Charge0
Complexity1950
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Fujian Genohope Biotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.

Flag China
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Company Banner

02

Transo-Pharm USA LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Transo Pharm USA Company Banner

03

Shanghai Minbiotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shanghai Minbiotech CB

04

Shandong Chenghui Shuangda Pharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChina’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Shandong Chenghui Shuangda Pharmaceutical

05

Lupin Manufacturing Solutions

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

06

Allsino Pharmaceutical Co. Ltd

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Annual COG
Not Confirmed
arrow

Allsino Pharmaceutical Co. Ltd

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Annual COG
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

07

Allsino Pharmaceutical Co. Ltd

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Annual COG
Not Confirmed
arrow

Allsino Pharmaceutical Co. Ltd

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Annual COG
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

08

Jiangsu Sinopep Allsino Biopharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Annual COG
Not Confirmed
arrow

Jiangsu Sinopep Allsino Biopharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Annual COG
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

09

Zydus Lifesciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Annual COG
Not Confirmed
arrow

10

Sichuan Taienkang Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Annual COG
Not Confirmed
arrow
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.

Flag China
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 42393

Submission : 2025-09-16

Status : Active

Type : II

Company Banner

02

BioProcess International US West
Not Confirmed

03

BioProcess International US West
Not Confirmed

04

BioProcess International US West
Not Confirmed

04

BioProcess International US West
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41815

Submission : 2025-04-27

Status : Active

Type : II

blank

05

Ningxia Labschem Co Ltd

Country

USDMF

arrow
BioProcess International US West
Not Confirmed

05

Ningxia Labschem Co Ltd

Country
arrow
BioProcess International US West
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 42012

Submission : 2025-05-26

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.

Flag China
Digital Content Digital Content

Orforglipron

About the Company : Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and provides global API and preparation manufacturing services. Co-founded by New Hop...

Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and provides global API and preparation manufacturing services. Co-founded by New Hope Hosencare Brothers and Taiwan Genovior Biotech Corporation, the company operates from the Cross-Strait Biotechnology and Health and Medical Industry Cooperation Zone in Fujian, China. With a 70,000-square-meter GMP-compliant facility and 11 production lines, it meets regulatory requirements for China, the U.S., and international markets. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content

Orforglipron

About the Company : Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and a...

Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and acts as a sourcing and regulatory marketing agent for API manufacturers. Transo-Pharm assists with DMF setup, GMP consulting, and regulatory activities, supported by a regulatory team, warehouse facilities, proprietary API process IPs, and laboratory partnerships, with offices in Shanghai, Hong Kong, Singapore, and the US. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Transo Pharm USA Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Orforglipron Calcium Hydrate

About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...

Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Shanghai Minbiotech CB

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChina’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

Flag China
Digital Content Digital Content

Orforglipron Calcium Hydrate

About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM services and Finished ...

Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM services and Finished Formulation Technology Transfer. With 24 years' expertise, our 6 GMP workshops ensure 100-ton monthly cGMP-compliant capacity. We hold 21 NMPA-registered APIs, 4 US-DMF filings, 8 CEP applications, and passed US FDA, Korea MFDS, and global client audits. Note: Patent-protected products are for R&D use only per Patent Act, not for commercial sale.
Shandong Chenghui Shuangda Pharmaceutical

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Flag India
Digital Content Digital Content

Orforglipron

About the Company : Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of ...

Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of pharma expertise, LMS combines cost efficiency with regulatory excellence. With world-class sites in Dabhasa and Vizag, and an R&D center in Pune, we deliver integrated, sustainable, and globally compliant solutions that accelerate drug development and reduce environmental impact. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

06

Natural Products Expo
Not Confirmed
arrow
arrow
Natural Products Expo
Not Confirmed

Orforglipron

About the Company : Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.is a high-tech enterprise, which is an integration of R & D, producing and custom synthesis. The products quality is assured ...

Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.is a high-tech enterprise, which is an integration of R & D, producing and custom synthesis. The products quality is assured because of our continuously-optimizing management and technology innovation, complete QA system, advanced testing methods and equipments. We have won the trust of a wide range of customers/partners in the industry. Our Products include active pharmaceutical ingredients (API), pharmaceutical and agrochemical intermediates and chiral compounds.
blank

07

Natural Products Expo
Not Confirmed
arrow
arrow
Natural Products Expo
Not Confirmed

Orforglipron Calcium Hydrate

About the Company : Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and effici...

Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and efficient manufacturing technologies, Sinopep ensures global compliance with advanced process development. Their CRDMO services span peptides, oligonucleotides, and synthetic conjugates, making them a trusted partner worldwide in pharmaceutical and healthcare solutions.
blank

08

Natural Products Expo
Not Confirmed
arrow
arrow
Natural Products Expo
Not Confirmed

Orforglipron Calcium Hydrate

About the Company : Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products...

Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products in the market and in the pipeline, MSN has 6 API (including Oncology) and one finished dosage facilities (one more for Oncology is being built) and an integrated R&D Center for Contract Research And Manufacturing Services (CRAMS) located in Hyderabad. MSN has won the trust of more than 250 customers across 65 countries around the globe covering the US, Europe, Latin America, Middle-East, Asia Pacific, Africa and CIS markets. Our product basket offers 100 APIs
blank

09

Natural Products Expo
Not Confirmed
arrow
arrow
Natural Products Expo
Not Confirmed

Orforglipron

About the Company : Nantong Quanyi Biotechnology Co., Ltd. is a technology-driven enterprise that seamlessly integrates research and development, production, and sales. The company has forged enduring...

Nantong Quanyi Biotechnology Co., Ltd. is a technology-driven enterprise that seamlessly integrates research and development, production, and sales. The company has forged enduring partnerships with renowned pharmaceutical and chemical firms, scientific research institutions, and university laboratories both domestically and internationally. Together, they are dedicated to tailored chemical synthesis, the creation of high-value pharmaceutical intermediates, and the research and development of new drugs. Nantong Quanyi Biotechnology is equipped to offer customized production services ranging from gram-level and kilogram-level quantities.
blank

10

Natural Products Expo
Not Confirmed
arrow
arrow
Natural Products Expo
Not Confirmed

Orforglipron Calcium Hydrate

About the Company : Sichuan Taienkang Pharmaceutical Co., Ltd., established in 2020, is a subsidiary of Guangdong Taienkang Pharmaceutical Co., Ltd. The company specializes in the R&D, production, and...

Sichuan Taienkang Pharmaceutical Co., Ltd., established in 2020, is a subsidiary of Guangdong Taienkang Pharmaceutical Co., Ltd. The company specializes in the R&D, production, and sales of generic APIs and intermediates, focusing on high-value APIs such as Dapoxetine Hydrochloride, Tadalafil, and others to meet diverse market needs. Located in the Yuechi Economic Development Zone, Sichuan Province, the manufacturing site spans 100 acres within a provincial-level chemical industry park. Phase one includes 4 independent production lines and a Class D GMP workshop, equipped with 500L to 5000L multifunctional reactors.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Orforglipron Calcium Hydrate is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Atherosclerosis.


Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 21, 2025

blank

01

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Details : Orforglipron Calcium Hydrate is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Atherosclerosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 21, 2025

blank

Details:

Orforglipron calcium hydrate is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Peripheral Arterial Disease.


Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 03, 2025

blank

02

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Details : Orforglipron calcium hydrate is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Peripheral Arterial Disease.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 03, 2025

blank

Details:

Orforglipron is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Urinary Incontinence,Stress.


Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable

Therapeutic Area: Urology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 02, 2025

blank

03

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Details : Orforglipron is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Urinary Incontinence,Stress.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 02, 2025

blank

Details:

Orforglipron Calcium Hydrate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Osteoarthritis.


Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable

Therapeutic Area: Musculoskeletal Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 04, 2025

blank

04

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Details : Orforglipron Calcium Hydrate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Osteoarthritis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 04, 2025

blank

Details:

Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Obesity.


Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable

Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 29, 2025

blank

05

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Details : Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Obesity.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 29, 2025

blank

Details:

Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.


Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable

Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 15, 2025

blank

06

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Details : Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 15, 2025

blank

Details:

Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.


Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable

Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 15, 2025

blank

07

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Details : Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 15, 2025

blank

Details:

Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.


Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 01, 2025

blank

08

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Details : Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 01, 2025

blank

Details:

Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.


Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 29, 2025

blank

09

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Details : Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 29, 2025

blank

Details:

Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.


Lead Product(s): Orforglipron Calcium Hydrate,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 29, 2025

blank

10

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Eli Lilly

U.S.A
arrow
Natural Products Expo
Not Confirmed

Details : Orforglipron is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 29, 2025

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions
The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications:     Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities:     Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program:     Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry. 

Impressions: 3516

https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions

#PharmaFlow by PHARMACOMPASS
13 Nov 2025

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar-control-and-weight-loss-compared-to-oral-semaglutide-in-head-to-head-type-2-diabetes-trial-published-in-the-lancet-302697632.html

PR NEWSWIRE
26 Feb 2026

https://www.fiercepharma.com/pharma/lillys-pre-launch-inventory-oral-glp-1-candidate-swells-ahead-expected-fda-obesity-nod

FIERCE PHARMA
13 Feb 2026

https://www.biospace.com/business/lilly-prepares-1b-orforglipron-stock-ahead-of-approval-as-novo-brings-wegovy-pill-overseas

BIOSPACE
13 Feb 2026

https://www.biospace.com/novos-wegovy-pill-success-is-good-news-for-orforglipron-lilly-execs-say

BIOSPACE
04 Feb 2026

https://www.reuters.com/sustainability/boards-policy-regulation/us-fda-delays-two-drug-reviews-new-voucher-program-after-safety-efficacy-2026-01-15/

REUTERS
17 Jan 2026

https://www.businesswire.com/news/home/20251106972503/en/BIOVECTRA-and-Revolution-Biomanufacturing-Partner-to-Deliver-Integrated-mRNA-Design-and-GMP-Production-Services

BUSINESSWIRE
08 Nov 2025

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for 2212020-52-3 / Orforglipron Calcium Hydrate API manufacturers, exporters & distributors?

Orforglipron Calcium Hydrate manufacturers, exporters & distributors 1

33

PharmaCompass offers a list of Orforglipron Calcium Hydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier.

PharmaCompass also assists you with knowing the Orforglipron Calcium Hydrate API Price utilized in the formulation of products. Orforglipron Calcium Hydrate API Price is not always fixed or binding as the Orforglipron Calcium Hydrate Price is obtained through a variety of data sources. The Orforglipron Calcium Hydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Orforglipron Calcium Hydrate

Synonyms

2212020-52-3, Ly3502970, Chembl4446782, Ly-3502970, 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one, 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one

Cas Number

2212020-52-3

Unique Ingredient Identifier (UNII)

7ZW40D021M

Orforglipron Manufacturers

A Orforglipron manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Orforglipron, including repackagers and relabelers. The FDA regulates Orforglipron manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Orforglipron API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Orforglipron manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Orforglipron Suppliers

A Orforglipron supplier is an individual or a company that provides Orforglipron active pharmaceutical ingredient (API) or Orforglipron finished formulations upon request. The Orforglipron suppliers may include Orforglipron API manufacturers, exporters, distributors and traders.

click here to find a list of Orforglipron suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Orforglipron USDMF

A Orforglipron DMF (Drug Master File) is a document detailing the whole manufacturing process of Orforglipron active pharmaceutical ingredient (API) in detail. Different forms of Orforglipron DMFs exist exist since differing nations have different regulations, such as Orforglipron USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Orforglipron DMF submitted to regulatory agencies in the US is known as a USDMF. Orforglipron USDMF includes data on Orforglipron's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Orforglipron USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Orforglipron suppliers with USDMF on PharmaCompass.

Orforglipron NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Orforglipron as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Orforglipron API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Orforglipron as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Orforglipron and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Orforglipron NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Orforglipron suppliers with NDC on PharmaCompass.

Orforglipron GMP

Orforglipron Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Orforglipron GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Orforglipron GMP manufacturer or Orforglipron GMP API supplier for your needs.

Orforglipron CoA

A Orforglipron CoA (Certificate of Analysis) is a formal document that attests to Orforglipron's compliance with Orforglipron specifications and serves as a tool for batch-level quality control.

Orforglipron CoA mostly includes findings from lab analyses of a specific batch. For each Orforglipron CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Orforglipron may be tested according to a variety of international standards, such as European Pharmacopoeia (Orforglipron EP), Orforglipron JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Orforglipron USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty